pI: 8.1755 |
Length (AA): 262 |
MW (Da): 27046 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
69 | 132 | 2k3n (A) | 5 | 65 | 38.00 | 0.068 | 0.06 | 0.445675 | 1.2 |
138 | 236 | 2e2z (A) | 1 | 93 | 40.00 | 0 | 1 | 0.804563 | -0.18 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | VEG Tachyzoite, ME49 Tachyzoite, ME49 merozoite, ME49 Oocyst. | Gregory Hehl AB Fritz HM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | ME49 Bradyzoite. | Sibley/Greg |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Gregory | ToxoDB |
Sibley/Greg | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Ortholog group members (OG5_128569)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G54826 | protein ZINC RIBBON 3 |
Babesia bovis | BBOV_I003780 | DNL zinc finger domain containing protein |
Brugia malayi | Bm1_00460 | DNL zinc finger family protein |
Candida albicans | CaO19_6917 | hypothetical protein |
Candida albicans | CaO19.6917 | potential DNL zinc finger protein similar to S. cerevisiae FMP28 (YNL310C) mitochondrial protein |
Cryptosporidium hominis | Chro.50487 | hypothetical protein |
Cryptosporidium parvum | cgd5_3660 | hypothetical conserved protein |
Dictyostelium discoideum | DDB_G0292818 | Zim17-type zinc finger-containing protein |
Drosophila melanogaster | Dmel_CG12379 | CG12379 gene product from transcript CG12379-RB |
Echinococcus granulosus | EgrG_000717800 | Zinc finger Zim17 type |
Echinococcus multilocularis | EmuJ_000717800 | Zinc finger, Zim17 type |
Homo sapiens | ENSG00000213221 | DNL-type zinc finger |
Leishmania braziliensis | LbrM.25.0680 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_250830.1 | DNL zinc finger, putative |
Leishmania infantum | LinJ.25.0830 | hypothetical protein, conserved |
Leishmania major | LmjF.25.0800 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.25.0800 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_00996 | DNL zinc finger family protein |
Mus musculus | ENSMUSG00000075467 | DNL-type zinc finger |
Oryza sativa | 4331164 | Os02g0819700 |
Plasmodium berghei | PBANKA_1022900 | DNL-type zinc finger protein, putative |
Plasmodium falciparum | PF3D7_1420300 | DNL-type zinc finger protein |
Plasmodium knowlesi | PKNH_1337700 | DNL-type zinc finger protein, putative |
Plasmodium vivax | PVX_085465 | hypothetical protein, conserved |
Plasmodium yoelii | PY01199 | Drosophila melanogaster CG12379 gene product |
Saccharomyces cerevisiae | YNL310C | Zim17p |
Schistosoma japonicum | Sjp_0200350 | DNL-type zinc finger protein, putative |
Schistosoma mansoni | Smp_117390 | hypothetical protein |
Schistosoma mansoni | Smp_191740 | hypothetical protein |
Trypanosoma brucei gambiense | Tbg972.3.2280 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.3.2300 | DNL zinc finger, putative |
Trypanosoma congolense | TcIL3000_0_42310 | DNL zinc finger containing protein, putative |
Trypanosoma cruzi | TcCLB.508479.274 | hypothetical protein, conserved |
Toxoplasma gondii | TGME49_260340 | DNL zinc finger protein |
Theileria parva | TP01_0459 | hypothetical protein, conserved |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.3.2300 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.3.2300 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.3.2300 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.3.2300 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
YNL310C | Saccharomyces cerevisiae | inviable | yeastgenome |
TGME49_260340 this record | Toxoplasma gondii | Essentiality uncertain | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.